ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2019
Identifying patients with NTRK fusion cancer.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 262 citations in OpenAlex.
- Pooled it
- Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial.Virchows Archiv : an international journal of pathology · 2021Trial
- Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice.Signal transduction and targeted therapy · 2026Review
- Next-Generation Sequencing Refines Diagnosis and Expands Precision Medicine Opportunities in Soft Tissue Sarcomas.International journal of molecular sciences · 2026Article
- Article
- Paediatric and Adult Solid Tumours Exhibiting NTRK Gene Fusions in Australia, 2020-2044: A Population-Based Statistical Modelling Study.Cancer medicine · 2026Article
- Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma.Signal transduction and targeted therapy · 2026Article
- Detection of NTRK gene fusions in sarcomas: a comparative study of Pan-TRK immunohistochemistry, FISH, and RNA-Based NGS.Pathologica · 2026Article
- Adult Low-Grade Glioma WithCase reports in pathology · 2026Article
- Article
- Evaluation ofInternational journal of molecular sciences · 2025Article
- Characteristics of extracellular vesicle-derived lncRNAs during the progression of HBV-related hepatocellular carcinoma.BMC cancer · 2025Article
- Seven Shades of Triple Negativity: A Review Unveiling the Low-Grade Spectrum of Breast Cancer.Cancers · 2025Review
- A case of primary ovarian clear cell carcinoma withInternational cancer conference journal · 2025Article
- NTRK protein expression in NSCLC and its clinicopathological correlation.Histology and histopathology · 2025Article
- Tumor Innervation: From Bystander to Emerging Therapeutic Target for Cancer.International journal of molecular sciences · 2025Review
- Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage.Molecular diagnosis & therapy · 2025Article
- A practical approach to better identify NTRK 1-3 fusion-positive mesenchymal neoplasms by pan-Trk immunohistochemistry.Virchows Archiv : an international journal of pathology · 2025Article
- Role of NTRK Fusion Genes in the Tumor Immune Microenvironment of HPV (+/-) Cervical Cancer.Journal of medical virology · 2025Review
- Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach.BMC cancer · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer. These oncogenic fusions occur when the kinase domain of NTRK1, NTRK2 or NTRK3 fuse with any of a number of N-terminal partners. NTRK fusions are characteristic of a few rare types of cancer, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, but they are also infrequently seen in some common cancers, such as melanoma, glioma and carcinomas of the thyroid, lung and colon. There are multiple methods for identifying NTRK fusions, including pan-TRK immunohistochemistry, fluorescence in situ hybridisation and sequencing methods, and the advantages and drawbacks of each are reviewed here. While testing algorithms will obviously depend on availability of various testing modalities and economic considerations for each individual laboratory, we propose triaging specimens based on histology and other molecular findings to most efficiently identify tumours harbouring these treatable oncogenic fusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.